Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi 'Fine-Tuning' Cialis OTC Switch Application

Executive Summary

Potential Cialis switch and the pending addition of Boehringer Ingelheim's consumer business are the revenue drivers highlighted by company execs on earnings call; second-quarter consumer health product revenues slipped 4.3% to $886.4m as a mild allergy season in the US and economic chaos in Venezuela drag down sales.

You may also be interested in...



Cialis Or Viagra Switch? Sanofi Survey, Pfizer Help Wanted Ad Could Be Signs

Viagra marketer Pfizer also could have nonprescription sales in sight as it recruits a "global sexual health" brand manager with responsibilities including shepherding market expansion through an Rx-to-OTC switch.

Cialis Or Viagra Switch? Sanofi Survey, Pfizer Help Wanted Ad Could Be Signs

Viagra marketer Pfizer also could have nonprescription sales in sight as it recruits a "global sexual health" brand manager with responsibilities including shepherding market expansion through an Rx-to-OTC switch.

Pharma Firm ISO OTC Switch Partner; NDA Experience, Resources Needed

Success in OTC switches can hinge on finding the right partner, say switch consultants during a CHPA webinar. Due diligence in negotiations can help determine if a potential partner is the right fit for the time- and labor-intensive processes.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS118882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel